NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Orca Bio

Orca Bio

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://orcabio.com/

Last Round

Series F

Jan 9, 2026

Est. Valuation

$2.4B

Total Funding Raised

$900M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Orca Bio is a biotechnology company that develops high-precision cell therapy products aimed at replacing diseased blood and immune systems with healthy ones.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

allogeneic cell therapycell therapyT-cell immunotherapygraft-versus-host diseaseGvHDstem cell transplantblood cancer treatmenthigh-precision cell sortingliving druggraft engineeringallogeneic hematopoietic stem cell transplantalloHSCTcell therapy manufacturinghematological malignanciesacute myeloid leukemiaAMLautoimmune disease treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Orca Bio Comparables

Compare Orca Bio with similar companies based on industry and business-model similarity.

Orca Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sana Biotechnology
76%
Vor Biopharma
71%
Gamida Cell Ltd.
71%

Orca Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series FJan 9, 2026
Series FDec 1, 2025
Series DJun 17, 2020
Series CMay 1, 2018

Key People

Founding team and executive leadership

Ivan Dimov

Co-Founder And CEO

Founding Team

Nathaniel Fernhoff

Chief Executive Officer And Co-founder, Co-Founder

Founding Team

Josh Murray

Chief Financial Officer And Head Of Strategy

Executive Team

Orca Bio Investors

Notable investors and investment history

Orca Bio investors
InvestorRounds
Kaiser Permanente Group TrustSeries D
DCVC BioSeries D, VC Round
Illinois Municipal Retirement FundSeries D
Kaiser Foundation HospitalsSeries D
ND CapitalSeries D
8VCSeries C, Series D, VC Round
Mubadala Investment CompanySeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 7, 2026

    Grew 17% QoQ, from 287 to 336 employees.

  • Apr 14, 2026

    Job posting suggests private company may be preparing for public offering.

Orca Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Orca Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Orca Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range336
Year Founded2016
Last FundingJan 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.